Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.
ABSTRACT Aberrant activation of the mammalian target of rapamycin (mTOR) pathway occurs in polycystic kidney disease (PKD). mTOR inhibitors, such as rapamycin, are highly effective in several rodent models of PKD, but these models result from mutations in genes other than Pkd1 and Pkd2, which are the primary genes responsible for human autosomal dominant PKD. To address this limitation, we tested the efficacy of rapamycin in a mouse model that results from conditional inactivation of Pkd1. Mosaic deletion of Pkd1 resulted in PKD and replicated characteristic features of human PKD including aberrant mTOR activation, epithelial proliferation and apoptosis, and progressive fibrosis. Treatment with rapamycin was highly effective: It reduced cyst growth, preserved renal function, inhibited epithelial cell proliferation, increased apoptosis of cyst-lining cells, and inhibited fibrosis. These data provide in vivo evidence that rapamycin is effective in a human-orthologous mouse model of PKD.
Full-textDOI: · Available from: Jonathan M. Shillingford, Ph.D., Jul 05, 2015
Click to see the full-text of:
Article: Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.
- [Show abstract] [Hide abstract]
ABSTRACT: The author presents the technology management FTTM (fast-time-to-market) model for continuous improvement of products, processes, and services to enhance quality, reduce costs, and improve time market, productivity, and total customer satisfaction. The four components of the model are described, including the blueprint for product and service FTTM objectives and technology management; a team approach to product and service development; continuous optimization of products and services, technologies, systems, and processes; and continuous evaluation and improvement of FTTM objectives and customer satisfaction arrangement. FTTM technology management for existing and new products and services encompasses certain boundaries and limits. It involves setting the right FTTM goals and objectives, and leveraging all resources and other business assets by continuous optimization of all work processes and functions of the business enterprise. It requires managing the totality of technology operation, product, and service requirements from concept to commercialization. FTTM technology management deals with many issues that affect a firms competitivenessTechnology Management : the New International Language; 11/1991
Conference Paper: The product-process-market path: new road maps[Show abstract] [Hide abstract]
ABSTRACT: Global competition is causing management to rethink the way design and production are done. To cut time to market, industry is aiming to shorten both the manufacturing and engineering cycles. New road maps are being developed and experimented with. It is noted that the traditional throw-it-over-the-wall road map has been discarded and the focus has turned to group technology, concurrent engineering, design for manufacture, and design for assembly. Dictaphone Corporation's products aim at the industrial voice recording market, and in late 1990 it formed a team to explore the feasibility of a new product. The team sized up the proposed product's technical feasibility by reviewing Dictaphone's analog/digital technology, PCB (printed circuit board) product process technology, and test requirements. The focus of the case study described is on PCB technology, the PCB being a component of the new product. The concept-design-production path is described. The PCB design-manufacture approach described here provides a road map aimed at product reliability and robustness as well as reduced cycle time, all of which means an improved competitive edge in the market placeTechnology Management : the New International Language; 11/1991
Conference Paper: Multinational issues in R&D management[Show abstract] [Hide abstract]
ABSTRACT: Summary form only given. It is pointed out that multinational R&D is more complex than single-location R&D. One must consider non R&D related factors, such as tax regimes, governmental influence, cultural differences, and modes of communication. Both internal and external influences determine how an organization will perform R&D. How these factors impact R&D management often depends on the size of the organization. In particular, mid-size companies with 500 to 2000 employees have both the most flexibility and the most difficulty in establishing and maintaining multinational R&D facilities. The author has considered R&D management for multinational organizations, examining multinational R&D finance, and giving a framework for its managementTechnology Management : the New International Language; 11/1991